Anna Dorottya Doleschall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Dorottya Doleschall has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Andreas Burchert
Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Marburg, Germany
1 shared publicationAndreas Hochhaus
Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
1 shared publication- Anne Brandenburg
Medical Clinic and Polyclinic III Internal Medicine With a Focus on Oncology, Hematology, and Rheumatology, University Hospital Bonn, University of Bonn, Bonn, Germany
1 shared publication Björn Steffen
Medizinische Klinik 2, Hämatologie/Onkologie, Goethe-Universität, Frankfurt am Main, Germany
1 shared publication- Christian Thiede
Department of Internal Medicine I, University Hospital Carl Gustav Carus University of Technology Dresden Germany
1 shared publication - Christoph Röllig
Technische Universität Dresden
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1783-1796
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1783-1796
Open AccessTreatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
- Open Access
- 28 July 2017
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 9 (35) , 5091-5093
Spiegelmers as potential receptors for cTnI diagnostics
We demonstrate the first application of a nuclease resistant aptamer, the so-called Spiegelmer, in a sandwich-type affinity assay by quantitative assessment of cardiac Troponin I (cTnI) in blood serum samples.
- 28 July 2017
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 9 (35) , 5091-5093
Open AccessSpiegelmers as potential receptors for cTnI diagnostics
We demonstrate the first application of a nuclease resistant aptamer, the so-called Spiegelmer, in a sandwich-type affinity assay by quantitative assessment of cardiac Troponin I (cTnI) in blood serum samples.